European Medicines Agency recommends Opdivo for treatment of earlier melanoma stages
Source: Healio, July 2023
- Opdivo (nivolumab) is a programmed cell death protein 1 (PD-1) inhibitor.
- If approved, it will be the only PD-1 inhibitor indicated as adjuvant therapy for stage 2B through stage 4 of resected melanoma.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Opdivo for melanoma treatment in patients aged 12 years and older, according to a Bristol Myers Squibb press release.
The Committee for Medicinal Products for Human Use (CHMP) recommendation will now go before the European Commission for review.